Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy
Authors:
- Heidi M CraneHCHeidi M Crane
- Stephen E Van RompaeySRStephen E Van Rompaey
- Mari M KitahataMKMari M Kitahata
- 24 April 2006
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (7) , 1019-1026
Abstract
To examine the effect of antiretroviral agents and clinical factors on the development of elevated blood pressure (BP). Observational cohort study of patients initiating their first HAART regimen. We evaluated mean BP prior to HAART and while receiving HAART in relation to antiretroviral classes and individual agents, and demographic and clinical characteristics including change in body mass index (BMI) while on HAART. We used logistic regression analysis to examine factors associated with elevated BP [≥ 10 mmHg increase in systolic BP (SBP), diastolic BP (DBP) or new diagnosis of hypertension]. Among 444 patients who had 4592 BP readings, 95 patients developed elevated SBP (n = 83), elevated DBP (n = 33), or a new diagnosis of hypertension (n = 11) after initiating HAART. In multivariate analysis, patients on lopinavir/ritonavir had the highest risk of developing elevated BP [odds ratio (OR), 2.5; P = 0.03] compared with efavirenz-based regimens. When change in BMI was added to the model, increased BMI was significantly associated with elevated BP (OR, 1.3; P = 0.02), and the association between lopinavir/ritonavir and elevated BP was no longer present. Compared with lopinavir/ritonavir-based regimens, patients receiving atazanavir (OR, 0.2; P = 0.03), efavirenz (OR, 0.4; P = 0.02), nelfinavir (OR, 0.3; P = 0.02), or indinavir (OR, 0.3; P = 0.01) had significantly lower odds of developing elevated BP. Treatment with lopinavir/ritonavir is significantly associated with elevated BP, an effect that appears to be mediated through an increase in BMI. Patients receiving atazanavir were least likely to develop elevated BP. The impact of antiretroviral medications on cardiovascular disease risk factors will increasingly influence treatment decisions.Keywords
This publication has 21 references indexed in Scilit:
- Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003AIDS, 2005
- Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrityNephrology Dialysis Transplantation, 2004
- Hypertension among HIV patientsJournal Of Hypertension, 2003
- High Prevalence of Metabolic Syndrome Among HIV–Infected Patients: Link With the Cardiovascular RiskJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Prevalence of Metabolic Syndrome Among HIV PatientsDiabetes Care, 2002
- Factors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2002
- Elevated blood pressure in subjects with lipodystrophyAIDS, 2001
- Metabolic complications associated with antiretroviral therapyAntiviral Research, 2001
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998